{"id":60970,"date":"2024-02-28T07:18:18","date_gmt":"2024-02-28T07:18:18","guid":{"rendered":"https:\/\/medsname.com\/selgin\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"selgin","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/selgin\/","title":{"rendered":"Selgin"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Rychl\u00e1 odpov\u011b\u010f<\/h3>\n

Selgin<\/strong> je peror\u00e1ln\u00ed selegilin<\/strong> (5 mg) tableta \u2014 selektivn\u00ed inhibitor monoaminooxid\u00e1zy typu B (MAO-B)<\/strong> pou\u017e\u00edvan\u00e1 k l\u00e9\u010db\u011b Parkinsonova choroba<\/strong>. Blokov\u00e1n\u00edm MAO-B v mozku zpomaluje rozklad dopaminu a pom\u00e1h\u00e1 prodlou\u017eit dobu, po kterou levodopa \u00fa\u010dinkuje mezi d\u00e1vkami (sni\u017euje \u201coff\u201d \u010das). Selegilin je metabolizov\u00e1n na L-amfetamin a L-metamfetamin<\/strong>, co\u017e m\u016f\u017ee p\u0159isp\u00edvat k nespavosti \u2014 u\u017e\u00edvejte pouze rann\u00ed d\u00e1vky. \u010cast\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky: nespavost, bolest hlavy, dyskineze, sucho v \u00fastech, ortostatick\u00e1 hypotenze. D\u016fle\u017eit\u00e9:<\/strong> Vyhn\u011bte se kombinaci s v\u011bt\u0161inou antidepresiv (SSRI, SNRI, TCA), opioidy, jako je pethidine a tramadol, a dextromethorphanem \u2014 riziko serotoninov\u00fd syndrom<\/em>.<\/p>\n<\/div>\n

\nCo z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n

Co je Selgin?<\/h2>\n

Selgin je peror\u00e1ln\u00ed tableta obsahuj\u00edc\u00ed selegilin 5 mg<\/strong>. Selegilin je selektivn\u00ed inhibitor monoaminooxid\u00e1zy typu B (MAO-B)<\/strong> Xadago Eldepryl \/ Jumex<\/strong>. Selgin je vyr\u00e1b\u011bn ve WHO-GMP certifikovan\u00e9m za\u0159\u00edzen\u00ed a je bioekvivalentn\u00ed p\u016fvodn\u00ed zna\u010dce ve stejn\u00e9 s\u00edle.<\/p>\n

Selegilin byl prvn\u00edm inhibitorem MAO-B pou\u017e\u00edvan\u00fdm u Parkinsonovy choroby, v klinick\u00e9m u\u017e\u00edv\u00e1n\u00ed od 80. let 20. stolet\u00ed. M\u016f\u017ee b\u00fdt pou\u017e\u00edv\u00e1n jako monoterapie<\/em> u \u010dasn\u00e9 Parkinsonovy nemoci (m\u00edrn\u00fd symptomatick\u00fd p\u0159\u00ednos, m\u016f\u017ee odd\u00e1lit pot\u0159ebu levodopy o m\u011bs\u00edce) nebo jako pomocn\u00fd prost\u0159edek<\/em> Selgin m\u016f\u017ee b\u00fdt metabolizov\u00e1n na L-amfetamin a L-methamfetamin, kter\u00e9 nez\u00e1visle p\u0159isp\u00edvaj\u00ed k m\u00edrn\u00e9mu stimula\u010dn\u00edmu a dopaminergick\u00e9mu \u00fa\u010dinku. Nad 10 mg\/den se ztr\u00e1c\u00ed selektivita pro MAO-B a inhibice MAO-A se st\u00e1v\u00e1 klinicky v\u00fdznamnou \u2014 omezen\u00ed tyraminu se st\u00e1v\u00e1 d\u016fle\u017eit\u00fdm.<\/p>\n

Jak funguje Selgin (selegiline)?<\/h2>\n

In the brain, dopamine is degraded mainly by monoamine oxidase type B (MAO-B). Selegiline irreversibly inactivates MAO-B at standard doses (5\u201310 mg\/day), so dopamine released from surviving neurones lingers longer in the synapse. The result: smoother symptom control and a longer benefit from each levodopa dose. Selegiline is also metabolised to L-amphetamine and L-methamphetamine, which independently contribute mild stimulant and dopaminergic effects. Above 10 mg\/day, selectivity for MAO-B is lost and MAO-A inhibition becomes clinically meaningful \u2014 tyramine restriction then becomes important.<\/p>\n

Srovn\u00e1n\u00ed inhibitor\u016f MAO-B<\/h2>\n

T\u0159i inhibitory MAO-B pou\u017e\u00edvan\u00e9 u Parkinsonovy choroby \u2014 selegilin, rasagilin a safinamid \u2014 sd\u00edlej\u00ed spole\u010dn\u00fd mechanismus \u00fa\u010dinku, ale v\u00fdznamn\u011b se li\u0161\u00ed v metabolitech, d\u00e1vkov\u00e1n\u00ed a klinick\u00e9m vyu\u017eit\u00ed:<\/p>\n\n\n\n\n\n\n\n\n\n
Vlastnost<\/th>\nSelegilin<\/th>\nRasagilin<\/th>\nSafinamid<\/th>\n<\/tr>\n<\/thead>\n
Typick\u00e1 d\u00e1vka<\/td>\n5\u201310 mg\/den<\/td>\n0,5\u20131 mg\/den<\/td>\n50\u2013100 mg\/den<\/td>\n<\/tr>\n
Aktivn\u00ed metabolity<\/td>\nAmphetamin + methamphetamin<\/td>\nAminoindan (neamfetaminov\u00fd)<\/td>\n\u017d\u00e1dn\u00fd stimula\u010dn\u00ed metabolit<\/td>\n<\/tr>\n
\u00da\u010dinek na glutam\u00e1t<\/td>\nNe<\/td>\nNe<\/td>\nAno<\/strong> \u2014 modulace sod\u00edkov\u00fdch kan\u00e1l\u016f\/uvol\u0148ov\u00e1n\u00ed glutam\u00e1tu<\/td>\n<\/tr>\n
Indikace<\/td>\nMonoterapie nebo dopln\u011bk<\/td>\nMonoterapie nebo dopln\u011bk<\/td>\nPouze jako dopln\u011bk<\/strong> \u2014 pro kol\u00edsav\u00fd pr\u016fb\u011bh Parkinsonovy choroby p\u0159i l\u00e9\u010db\u011b levodopou<\/td>\n<\/tr>\n
Riziko nespavosti<\/td>\nVy\u0161\u0161\u00ed (metabolity amfetaminu)<\/td>\nN\u00edzk\u00e1<\/td>\nN\u00edzk\u00e1<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Pro koho je Selgin vhodn\u00fd?<\/h2>\n

Selgin je vhodn\u00fd pro dosp\u011bl\u00e9 s Parkinsonovou chorobou \u2014 bu\u010f jako po\u010d\u00e1te\u010dn\u00ed monoterapie v ran\u00e9m st\u00e1diu onemocn\u011bn\u00ed (kdy jsou p\u0159\u00edznaky m\u00edrn\u00e9 a pacient se zdr\u00e1h\u00e1 za\u010d\u00edt s levodopou) nebo jako dopln\u011bk k levodop\u011b u pacient\u016f s \u201cvyvanut\u00edm\u201d \u00fa\u010dinku na konci d\u00e1vkov\u00e1n\u00ed. Star\u0161\u00ed pacienti n\u00e1chyln\u00ed k nespavosti mohou l\u00e9pe sn\u00e1\u0161et rasagilin nebo safinamid. Nevhodn\u00fd b\u011bhem sou\u010dasn\u00e9 terapie SSRI\/SNRI\/TCA nebo pro pacienty pl\u00e1nuj\u00edc\u00ed u\u017e\u00edvat petidin, tramadol nebo jin\u00e9 kontraindikovan\u00e9 l\u00e9ky.<\/p>\n

D\u00e1vkov\u00e1n\u00ed a pod\u00e1v\u00e1n\u00ed<\/h2>\n

Standardn\u00ed d\u00e1vka pro dosp\u011bl\u00e9 je 5 mg jednou denn\u011b p\u0159i sn\u00eddani<\/strong>, zv\u00fd\u0161it na 5 mg dvakr\u00e1t denn\u011b (sn\u00eddan\u011b a ob\u011bd) po 1\u20132 t\u00fddnech<\/strong> v p\u0159\u00edpad\u011b pot\u0159eby pro kontrolu p\u0159\u00edznak\u016f. Vyhn\u011bte se ve\u010dern\u00edm d\u00e1vk\u00e1m<\/em> \u2014 amfetaminov\u00e9 metabolity zp\u016fsobuj\u00ed nespavost. Maxim\u00e1ln\u011b 10 mg\/den p\u0159i standardn\u00ed selektivit\u011b MAO-B. D\u00e1vky a\u017e 20\u201330 mg\/den se historicky pou\u017e\u00edvaly, ale p\u0159ekra\u010duj\u00ed do neselektivn\u00ed inhibice MAO s pln\u00fdmi d\u016fsledky pro tyraminovou dietu.<\/p>\n\n\n\n\n\n\n\n
F\u00e1ze<\/th>\nD\u00e1vka<\/th>\nNa\u010dasov\u00e1n\u00ed<\/th>\n<\/tr>\n<\/thead>\n
T\u00fdden 1\u20132 (zah\u00e1jen\u00ed)<\/td>\n5 mg jednou denn\u011b<\/td>\nP\u0159i sn\u00eddani<\/td>\n<\/tr>\n
Udr\u017eovac\u00ed d\u00e1vka<\/td>\n5 mg dvakr\u00e1t denn\u011b<\/td>\nSn\u00eddan\u011b a ob\u011bd \u2014 nikdy ve\u010der<\/td>\n<\/tr>\n
Maximum p\u0159i selektivit\u011b MAO-B<\/td>\n10 mg\/den<\/td>\nNad tuto hranici je nutn\u00e1 restrikce tyraminu<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\u26a0 Tyramin a \u201cs\u00fdrov\u00fd efekt\u201d<\/strong> P\u0159i standardn\u00edch d\u00e1vk\u00e1ch selektivn\u00edch k MAO-B nen\u00ed obvykle nutn\u00e1 dietn\u00ed restrikce tyraminu. ne<\/em> Nutn\u00e9. Selektivita MAO-B je v\u0161ak z\u00e1visl\u00e1 na d\u00e1vce \u2014 selegilin nad 10 mg\/den, rasagilin nad 1 mg\/den a safinamid nad 100 mg\/den ztr\u00e1cej\u00ed selektivitu a inhibuj\u00ed tak\u00e9 perifern\u00ed MAO-A. P\u0159i t\u011bchto d\u00e1vk\u00e1ch mohou potraviny bohat\u00e9 na tyramin (zraj\u00edc\u00ed s\u00fdry, uzen\u00e9 maso, bobovit\u00e9 rostliny, fermentovan\u00e1 s\u00f3ja, to\u010den\u00e9 pivo) vyvolat hypertenzn\u00ed krizi. Dodr\u017eujte p\u0159edepsan\u00e9 d\u00e1vkov\u00e1n\u00ed, abyste se tomuto riziku vyhnuli.<\/div>\n

B\u011b\u017en\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky<\/h2>\n

Nespavost (velmi \u010dast\u00e1 \u2014 nej\u010dast\u011bj\u0161\u00ed d\u016fvod k ukon\u010den\u00ed l\u00e9\u010dby), bolest hlavy, nevolnost, z\u00e1vrat\u011b, ortostatick\u00e1 hypotenze, sucho v \u00fastech, zv\u00fd\u0161en\u00e9 jatern\u00ed enzymy. M\u00e9n\u011b \u010dast\u00e9: zmatenost, halucinace, agitovanost, zm\u011bny n\u00e1lady. P\u0159i u\u017e\u00edv\u00e1n\u00ed levodopy: zv\u00fd\u0161en\u00e9 dyskineze, m\u016f\u017ee b\u00fdt nutn\u00e9 sn\u00ed\u017eit d\u00e1vku levodopy o 10\u201330%.<\/p>\n

\u26a0 Serotoninov\u00fd syndrom \u2014 nebezpe\u010dn\u00e9 interakce<\/strong> Kombinace inhibitoru MAO-B se serotonergn\u00edmi l\u00e9ky m\u016f\u017ee zp\u016fsobit serotoninov\u00fd syndrom<\/em>: neklid, pocen\u00ed, t\u0159es, hyperreflexie, hore\u010dka, pr\u016fjem, v t\u011b\u017ek\u00fdch p\u0159\u00edpadech z\u00e1chvaty a smrt. Vyvarujte se:<\/strong> SSRI (fluoxetin, sertralin, paroxetin, citalopram, escitalopram), SNRI (venlafaxin, duloxetin), tricyklick\u00e1 antidepresiva (amitriptylin, imipramin), pethidin (meperidin), tramadol, dextromethorfan, methadon, t\u0159ezalka te\u010dkovan\u00e1, MDMA. Vylu\u010dovac\u00ed obdob\u00ed:<\/strong> p\u0159eru\u0161it u\u017e\u00edv\u00e1n\u00ed fluoxetinu 5 t\u00fddn\u016f p\u0159ed zah\u00e1jen\u00edm inhibitoru MAO-B; ostatn\u00ed SSRI\/SNRI p\u0159eru\u0161it alespo\u0148 2 t\u00fddny p\u0159edem; neza\u010d\u00ednat s fluoxetinem d\u0159\u00edve ne\u017e 2 t\u00fddny po ukon\u010den\u00ed inhibitoru MAO-B.<\/div>\n

Interakce s l\u00e9ky a potravinami<\/h2>\n